| __timestamp | Amneal Pharmaceuticals, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 40786000 |
| Thursday, January 1, 2015 | 109679000 | 47876000 |
| Friday, January 1, 2016 | 118757000 | 52035000 |
| Sunday, January 1, 2017 | 109046000 | 55348000 |
| Monday, January 1, 2018 | 230435000 | 65276000 |
| Tuesday, January 1, 2019 | 289598000 | 82720000 |
| Wednesday, January 1, 2020 | 326727000 | 89118000 |
| Friday, January 1, 2021 | 365504000 | 181193000 |
| Saturday, January 1, 2022 | 399700000 | 174078000 |
| Sunday, January 1, 2023 | 429675000 | 184232000 |
Unlocking the unknown
In the competitive pharmaceutical and biotech sectors, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amneal Pharmaceuticals, Inc. and Veracyte, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, reflecting its aggressive expansion strategy. In contrast, Veracyte's costs increased by approximately 350%, indicating a more measured approach.
Amneal's expenses peaked in 2023, reaching nearly 430 million, while Veracyte's highest was around 184 million in the same year. Despite Amneal's higher absolute costs, its growth rate in SG&A expenses was more controlled in recent years, suggesting improved efficiency. Veracyte, meanwhile, maintained a steady increase, aligning with its strategic growth in the diagnostics market. This data underscores the importance of strategic cost management in sustaining competitive advantage.
Comparing SG&A Expenses: Pfizer Inc. vs Veracyte, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Veracyte, Inc.
Takeda Pharmaceutical Company Limited and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Veracyte, Inc. Trends and Insights
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bio-Techne Corporation vs Amneal Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Pharming Group N.V. vs Veracyte, Inc.
Amneal Pharmaceuticals, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Ultragenyx Pharmaceutical Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and Evotec SE